Clinical Reasoning: Assessing New Neurologic Deficits in Patients With Hematologic Malignancy on Bruton Tyrosine Kinase Inhibitor Therapy

Neurology. 2024 Nov 12;103(9):e209929. doi: 10.1212/WNL.0000000000209929. Epub 2024 Oct 4.

Affiliation

¹ From the Division of Neuro-Oncology (T.A.N., N.K.M., I.C.A.-R., N.W., J.D.), Department of Neurology; Department of Pathology (M.M.-L.A.); Division of Hematology and Oncology (J.A., A.R.B., Y.J., Y.-B.A.C.), Department of Medicine; Division of Infectious Diseases (A.R.L.), Department of Medicine; and Department of Neurosurgery (B.V.N.), Massachusetts General Hospital, Boston.

PMID: 39365973
DOI: 10.1212/WNL.0000000000209929

No abstract available

Publication types

Case Reports

MeSH terms

Agammaglobulinaemia Tyrosine Kinase* / antagonists & inhibitors
Clinical Reasoning
Female
Hematologic Neoplasms / complications
Hematologic Neoplasms / drug therapy
Humans
Male
Middle Aged
Nervous System Diseases / etiology
Protein Kinase Inhibitors* / adverse effects
Protein Kinase Inhibitors* / therapeutic use
Tyrosine Kinase Inhibitors

Substances

Agammaglobulinaemia Tyrosine Kinase
Protein Kinase Inhibitors
Tyrosine Kinase Inhibitors